Trials / Completed
CompletedNCT01733238
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
PNT2258-02: A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Sierra Oncology LLC - a GSK company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It study is a multi-center, nonrandomized, open-label, pilot Phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory lymphoma.
Detailed description
PNT2258 will be administered at a dose of 120 mg/m2, as a 3-hour intravenous (IV) infusion on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PNT2258 |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2012-11-26
- Last updated
- 2023-06-22
- Results posted
- 2020-03-10
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01733238. Inclusion in this directory is not an endorsement.